secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001104659-23-084468
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia submits NDA amendment to add PH-ILD indication for YUTREPIA; no new clinical data
--------------------------------------------------------------------------------

- Submitted amendment to add PH-ILD indication to tentatively approved NDA for YUTREPIA; no new clinical data needed.
- Final approval of PH-ILD indication possible after Tyvaso exclusivity expires March 31, 2024.
- Recertified paragraph IV that YUTREPIA does not infringe Tyvaso patents; all prior patent challenges won.
- Preparing for potential YUTREPIA launch between end of 2023 and mid-2024.
- Third Amendment to HCR financing: $10M second tranche received; future tranches require mutual agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/0001104659-23-084468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/tm2322220d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-084468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer